{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:40:08Z","timestamp":1791438008364,"version":"4.3.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:00:00Z","timestamp":1447891200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s10585-015-9770-x","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T00:55:07Z","timestamp":1447894507000},"page":"211-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo"],"prefix":"10.1007","volume":"33","author":[{"given":"I.","family":"Holen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Nutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Ottewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,19]]},"reference":[{"issue":"23","key":"9770_CR1","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-13-0838","volume":"19","author":"XH Zhang","year":"2013","unstructured":"Zhang XH, Giuliano M, Trivedi MV, Schiff R, Osborne CK (2013) Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res 19(23):6389\u20136397","journal-title":"Clin Cancer Res"},{"issue":"3\u20134","key":"9770_CR2","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10555-012-9378-4","volume":"31","author":"KL Kretschmann","year":"2012","unstructured":"Kretschmann KL, Welm AL (2012) Metastasis dormancy in estrogen receptor-positive breast cancer. Cancer Metastasis Rev 31(3\u20134):579\u2013583","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"9770_CR3","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2174\/156800909789760339","volume":"9","author":"HK Brown","year":"2009","unstructured":"Brown HK, Holen I (2009) Anti-tumour effects of bisphosphonates\u2013what have we learned from in vivo models? Curr Cancer Drug Targets 9(7):807\u2013823","journal-title":"Curr Cancer Drug Targets"},{"issue":"9","key":"9770_CR4","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E et al (2014) AZURE investigators. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol 15(9):997\u20131006","journal-title":"Lancet Oncol"},{"issue":"15","key":"9770_CR5","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M et al (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365(15):1396\u20131405","journal-title":"N Engl J Med"},{"issue":"2","key":"9770_CR6","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P et al (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24(2):398\u2013405","journal-title":"Ann Oncol"},{"issue":"7","key":"9770_CR7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, P\u00f6stlberger S, Menzel C et al (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7):679\u2013691","journal-title":"N Engl J Med"},{"issue":"5","key":"9770_CR8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2007.07.025","volume":"130","author":"T Nakamura","year":"2007","unstructured":"Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K et al (2007) Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 130(5):811\u2013823","journal-title":"Cell"},{"issue":"4","key":"9770_CR9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cmet.2007.09.007","volume":"6","author":"DV Novack","year":"2007","unstructured":"Novack DV (2007) Estrogen and bone: osteoclasts take center stage. Cell Metab 6(4):254\u2013256","journal-title":"Cell Metab"},{"issue":"9","key":"9770_CR10","first-page":"3128","volume":"82","author":"A Tomkinson","year":"1997","unstructured":"Tomkinson A, Reeve J, Shaw RW, Noble BS (1997) The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab 82(9):3128\u20133135","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"9770_CR11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.cmet.2007.09.007","volume":"6","author":"S Kousteni","year":"2007","unstructured":"Kousteni S, Chen JR, Bellido T, Han L, Ali AA, O\u2019Brien CA et al (2007) Reversal of bone loss in mice by nongenotropic signaling of sex steroids. Cell Metab 6(4):254\u2013256","journal-title":"Cell Metab"},{"issue":"5","key":"9770_CR12","first-page":"719","volume":"104","author":"S Kousteni","year":"2001","unstructured":"Kousteni S, Bellido T, Plotkin LI, O\u2019Brien CA, Bodenner DL, Han L, Han K et al (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104(5):719\u2013730","journal-title":"Cell"},{"issue":"37","key":"9770_CR13","doi-asserted-by":"crossref","first-page":"27285","DOI":"10.1074\/jbc.M702810200","volume":"282","author":"M Almeida","year":"2007","unstructured":"Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, Roberson PK et al (2007) Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 282(37):27285\u201327297","journal-title":"J Biol Chem"},{"issue":"5","key":"9770_CR14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S8756-3282(01)00412-4","volume":"28","author":"HL Benford","year":"2001","unstructured":"Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28(5):465\u2013473","journal-title":"Bone"},{"key":"9770_CR15","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bone.2014.06.023","volume":"66","author":"MT Haider","year":"2014","unstructured":"Haider MT, Holen I, Dear TN, Hunter K, Brown HK (2014) Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis. Bone 66:240\u2013250","journal-title":"Bone"},{"issue":"11","key":"9770_CR16","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1158\/1078-0432.CCR-13-1246","volume":"20","author":"PD Ottewell","year":"2014","unstructured":"Ottewell PD, Wang N, Brown HK, Reeves KJ, Fowles CA, Croucher PI et al (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 20(11):2922\u20132932","journal-title":"Clin Cancer Res"},{"key":"9770_CR17","doi-asserted-by":"crossref","unstructured":"Ottewell PD, Wang N, Brown HK, Fowles CA, Croucher PI, Eaton CL, Holen I (2015) OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int J Cancer. (Epub ahead of print)","DOI":"10.1002\/ijc.29439"},{"issue":"3","key":"9770_CR18","doi-asserted-by":"crossref","first-page":"R86","DOI":"10.1186\/bcr3201","volume":"14","author":"I Holen","year":"2012","unstructured":"Holen I, Whitworth J, Nutter F, Evans A, Brown HK, Lefley DV et al (2012) Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Res 14(3):R86","journal-title":"Breast Cancer Res"},{"issue":"3","key":"9770_CR19","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/jcp.22190","volume":"224","author":"JM Fleming","year":"2010","unstructured":"Fleming JM, Miller TC, Meyer MJ, Ginsburg E, Vonderhaar BK (2010) Local regulation of human breast xenograft models. J Cell Physiol 224(3):795\u2013806","journal-title":"J Cell Physiol"},{"issue":"8","key":"9770_CR20","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","volume":"82","author":"SG Senaratne","year":"2000","unstructured":"Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82(8):1459\u20131468","journal-title":"Br J Cancer"},{"issue":"11","key":"9770_CR21","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","volume":"15","author":"O Fromigue","year":"2000","unstructured":"Fromigue O, Lagneaux L, Body JJ (2000) Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15(11):2211\u20132221","journal-title":"J Bone Miner Res"},{"issue":"4","key":"9770_CR22","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/CAD.0b013e3282f632bf","volume":"19","author":"H M\u00f6nkk\u00f6nen","year":"2008","unstructured":"M\u00f6nkk\u00f6nen H, Kuokkanen J, Holen I, Evans A, Lefley DV, Jauhiainen M et al (2008) Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 19(4):391\u2013399","journal-title":"Anticancer Drugs"},{"issue":"1","key":"9770_CR23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1475-2867-12-48","volume":"12","author":"T Ibrahim","year":"2012","unstructured":"Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P et al (2012) Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int 12(1):48","journal-title":"Cancer Cell Int"},{"issue":"12","key":"9770_CR24","first-page":"5295","volume":"33","author":"L Muinelo-Romay","year":"2013","unstructured":"Muinelo-Romay L, Garcia D, Alonso-Alconada L, Vieito M, Carmona M, Mart\u00ednez N et al (2013) Zoledronic acid as an antimetastatic agent for different human tumor cell lines. Anticancer Res 33(12):5295\u20135300","journal-title":"Anticancer Res"},{"issue":"9","key":"9770_CR25","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1111\/j.1582-4934.2012.01527.x","volume":"16","author":"L Insalaco","year":"2012","unstructured":"Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR et al (2012) Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med 16(9):2186\u20132195","journal-title":"J Cell Mol Med"},{"issue":"9","key":"9770_CR26","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.18632\/oncotarget.1201","volume":"4","author":"E Rietk\u00f6tter","year":"2013","unstructured":"Rietk\u00f6tter E, Menck K, Bleckmann A, Farhat K, Schaffrinski M, Schulz M et al (2013) Zoledronic acid inhibits macrophage\/microglia-assisted breast cancer cell invasion. Oncotarget 4(9):1449\u20131460","journal-title":"Oncotarget"},{"issue":"3","key":"9770_CR27","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s12094-011-0634-9","volume":"13","author":"J Bosch-Barrera","year":"2011","unstructured":"Bosch-Barrera J, Merajver SD, Men\u00e9ndez JA, Van Poznak C (2011) Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clin Transl Oncol 13(3):148\u2013155","journal-title":"Clin Transl Oncol"},{"issue":"Suppl 1","key":"9770_CR28","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S1040-8428(11)70003-8","volume":"77","author":"JR Green","year":"2011","unstructured":"Green JR, Guenther A (2011) The backbone of progress\u2013preclinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 77(Suppl 1):S3\u2013S12","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"9770_CR29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/bcr3223","volume":"14","author":"RA Steinman","year":"2012","unstructured":"Steinman RA, Brufsky AM, Oesterreich S (2012) Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? Breast Cancer Res 14(5):213","journal-title":"Breast Cancer Res"},{"issue":"11","key":"9770_CR30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","volume":"42","author":"T Chen","year":"2002","unstructured":"Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42(11):1228\u20131236","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"9770_CR31","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","volume":"80","author":"MJ Rogers","year":"1997","unstructured":"Rogers MJ, Watts DJ, Russell RGG (1997) Overview of bisphosphonates. Cancer 80(8):1652\u20131660","journal-title":"Cancer"},{"issue":"4","key":"9770_CR32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","volume":"99","author":"F Daubin\u00e9","year":"2007","unstructured":"Daubin\u00e9 F, Le Gall C, Gasser J, Green J, Cl\u00e9zardin P (2007) Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 99(4):322\u2013330","journal-title":"J Natl Cancer Inst"},{"issue":"14","key":"9770_CR33","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1158\/1078-0432.CCR-07-1545","volume":"14","author":"PD Ottewell","year":"2008","unstructured":"Ottewell PD, Deux B, M\u00f6nkk\u00f6nen H, Cross S, Coleman RE, Clezardin P, Holen I (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 14(14):4658\u20134666","journal-title":"Clin Cancer Res"},{"issue":"16","key":"9770_CR34","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","volume":"100","author":"PD Ottewell","year":"2008","unstructured":"Ottewell PD, M\u00f6nkk\u00f6nen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100(16):1167\u20131178","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"9770_CR35","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ijc.24756","volume":"126","author":"PD Ottewell","year":"2010","unstructured":"Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 126(2):522\u2013532","journal-title":"Int J Cancer"},{"issue":"2","key":"9770_CR36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10549-011-1782-x","volume":"133","author":"PD Ottewell","year":"2012","unstructured":"Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ et al (2012) Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast Cancer Res Treat 133(2):523\u2013536","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"9770_CR37","first-page":"2949","volume":"60","author":"S Boissier","year":"2000","unstructured":"Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M et al (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60(11):2949\u20132954","journal-title":"Cancer Res"},{"issue":"12","key":"9770_CR38","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1016\/j.bbagen.2012.07.013","volume":"20","author":"PG Dedes","year":"2012","unstructured":"Dedes PG, Gialeli Ch, Tsonis AI, Kanakis I, Theocharis AD, Kletsas D et al (2012) Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta 20(12):1926\u20131939","journal-title":"Biochim Biophys Acta"},{"key":"9770_CR39","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.4049\/jimmunol.166.9.5508","volume":"166","author":"F Miyagawa","year":"2001","unstructured":"Miyagawa F, Tanaka Y, Yamashita S, Minato N (2001) Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 166:5508\u20135514","journal-title":"J Immunol"},{"key":"9770_CR40","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","volume":"102","author":"F Dieli","year":"2003","unstructured":"Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F et al (2003) Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102:2310\u20132311","journal-title":"Blood"},{"key":"9770_CR41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","volume":"197","author":"HJ Gober","year":"2003","unstructured":"Gober HJ, Kistowska M, Angman L, Jeno P, Mori L, De Libero G (2003) Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 197:163\u2013168","journal-title":"J Exp Med"},{"issue":"8","key":"9770_CR42","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1210\/jc.2010-0856","volume":"95","author":"S Khosla","year":"2010","unstructured":"Khosla S (2010) Update on estrogens and the skeleton. J Clin Endocrinol Metab 95(8):3569\u20133577","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-015-9770-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10585-015-9770-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-015-9770-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T13:56:42Z","timestamp":1567346202000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10585-015-9770-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,19]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["9770"],"URL":"https:\/\/doi.org\/10.1007\/s10585-015-9770-x","relation":{},"ISSN":["0262-0898","1573-7276"],"issn-type":[{"value":"0262-0898","type":"print"},{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,19]]}}}